Pharmacovigilance européenne des médicaments de thérapie innovante
Annales Pharmaceutiques Françaises · 2025
DOI: 10.1016/j.pharma.2025.02.011 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annales Pharmaceutiques Françaises, 2025. Verfasst von Nadine Petitpain und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hôpitaux de Brabois, centre régional de pharmacovigilance de Nancy, CHRU de Nancy, 54511 Vandœuvre-lès-Nancy cedex, France. Electronic address: crpv@…. Hauptthemen laut MEDLINE: Pharmacovigilance. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Advanced therapy medicinal products (ATMPs) are playing an increasingly important role in therapeutics, and sometimes represent the only hope of improving or even curing some pathologies. Because of their biological origin, composition, mode of action, and their frequent technical complexity, ATMPs are potentially generating new risks. Moreover, clinical trial data generally concern only a very small number of patients. The pharmacovigilance of ATMPs must adapt to these constraints and to these new identified or potential risks to be authorized according to an European centralized procedure. The conception and the assessment of the Risk Management Plan are essential to complete routine pharmacovigilance with post-authorization studies and additional risk minimisation measures adapted to the identified safety concerns. This article provides an overview of existing ATMPs and their specific regulatory pharmacovigilance requirements, involving the role of the European committees. It aims to describe the essential elements of the risk management plan of ATMPS, with a focus on delayed adverse reactions. The particular case of ATMPs prepared in the context of « hospital exemption », is also addressed, with the example of ATMPs for adoptive immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hôpitaux de Brabois, centre régional de pharmacovigilance de Nancy, CHRU de Nancy, 54511 Vandœuvre-lès-Nancy cedex, France. Electronic address: crpv@chru-nancy.fr.
- Hôpitaux de Brabois, centre régional de pharmacovigilance de Nancy, CHRU de Nancy, 54511 Vandœuvre-lès-Nancy cedex, France.
- Unité de thérapie cellulaire & banque de tissus, sang placentaire, CHRU de Nancy, hôpitaux de Brabois, 54511 Vandœuvre-lès-Nancy cedex, France.
- Délégation à la recherche clinique et à l'innovation, CHRU de Nancy, hôpitaux de Brabois, 54511 Vandœuvre-lès-Nancy cedex, France.
- Unité de transplantation médullaire, département d'oncohematologie pédiatrique, CHRU de Nancy, hôpitaux de Brabois, Vandœuvre-lès-Nancy cedex, France.
- GHU AP-HP Nord et université de Paris, hôpital Robert-Debré, Paris, France.
Zitieren
APA
Petitpain, N., Prontskus, V., Gauthier, M., Loutterbach, L., Pochon, C., Dalle, J. H., & Bensoussan, D. (2025). Pharmacovigilance européenne des médicaments de thérapie innovante. Annales Pharmaceutiques Françaises. https://doi.org/10.1016/j.pharma.2025.02.011
Vancouver
Petitpain N, Prontskus V, Gauthier M, Loutterbach L, Pochon C, Dalle JH, et al. Pharmacovigilance européenne des médicaments de thérapie innovante. Annales Pharmaceutiques Françaises. 2025. doi:10.1016/j.pharma.2025.02.011
BibTeX
@article{Petitpain2025,
author = {Petitpain, Nadine and Prontskus, Viktoryia and Gauthier, Mélanie and Loutterbach, Lena and Pochon, Cécile and Dalle, Jean Hugues and Bensoussan, Danièle},
title = {Pharmacovigilance européenne des médicaments de thérapie innovante},
journal = {Annales Pharmaceutiques Françaises},
year = {2025},
doi = {10.1016/j.pharma.2025.02.011}
}
EUVIMED